What is REGENXBIO?
REGENXBIO Inc., established in 2008 and headquartered in Rockville, Maryland, is a clinical-stage biotechnology firm dedicated to the development and commercialization of gene therapy products. The company leverages its proprietary adeno-associated virus (AAV) vector technology to create potentially curative treatments for a range of serious diseases. Its focus areas include ophthalmology, neurodegenerative diseases, and metabolic disorders, positioning it as a key player in the rapidly evolving gene therapy landscape.
How much funding has REGENXBIO raised?
REGENXBIO has raised a total of $138.6M across 1 funding round:
Stock Offering
$138.6M
Stock Issuance/Offering (2015): $138.6M, investors not publicly disclosed
What's next for REGENXBIO?
The substantial enterprise-level funding and recent strategic investment indicate a strong validation of REGENXBIO's technology and therapeutic approach. This capital infusion is expected to accelerate the company's clinical development programs, potentially enabling further expansion into new indications and the progression of its lead product candidates through late-stage trials. The company's strategic financing suggests a focus on scaling operations and advancing its pipeline towards commercialization, aiming to address unmet medical needs with innovative gene therapies.
See full REGENXBIO company page
